Inherent Biosciences

Inherent Biosciences is a private, commercial-stage diagnostics company leveraging epigenetic profiling and AI to create predictive tests for reproductive health. Its flagship product, SpermQT, marketed through its Path Fertility division, analyzes epigenetic patterns in sperm to provide personalized fertility insights and treatment guidance. The company is backed by a team of molecular biologists, data scientists, and clinical advisors, with ambitions to expand its epigenetic platform into other disease indications beyond reproductive health.

AI-driven epigenetic profiling platform that analyzes modifications to DNA and associated proteins to identify patterns correlating with biological function and disease outcomes.

In the male fertility diagnostics space, competition includes standard semen analysis providers and emerging molecular tests focusing on DNA fragmentation. Broader competition in epigenetic diagnostics comes from large genomic companies (e.g., Illumina's spin-offs) and specialized startups, all vying to establish clinically validated epigenetic biomarkers across various diseases.